If your plan said no to a GLP-1 for weight loss, it is worth knowing that "weight loss" is only one of the reasons these medicines can be prescribed. The FDA has approved some of them for other conditions too. A plan that will not pay for weight treatment may still pay for the exact same injection when you are being treated for something else.
This is not a loophole or a workaround. It only applies if you genuinely have the condition and your clinician documents it. But a lot of people are never told these other routes exist, so they take the first denial as the final word.
Why "weight loss" is the hardest reason to get covered
There is a specific reason weight loss sits at the bottom of the pile, and it is written into federal law. Social Security Act section 1927(d)(2) lists categories of drugs that a state Medicaid program is allowed to leave out of its coverage. One of those categories is "agents when used for anorexia, weight loss, or weight gain."
States are permitted to exclude them. They are not required to. That single word, permitted, is why coverage looks so different depending on where you live. Many commercial and employer plans carry a similar exclusion for weight management, written into the plan documents rather than the law.
So a denial that says weight loss is "not a covered benefit" is often not a judgement about you or your health. It is a category exclusion that was decided before your request was ever filed. Appealing the weight loss decision on medical grounds will usually not move it. Coming at it from a different, covered condition sometimes will.
Route one: heart disease, using Wegovy
On March 8, 2024, the FDA approved Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have known heart disease and are overweight or obese. The approval came out of the SELECT trial, which followed 17,604 people.
This matters for coverage because it moves the request out of the weight management category entirely. You are no longer asking your plan to treat obesity. You are asking it to reduce the risk of a heart attack in someone who has already been diagnosed with heart disease. Plans that exclude weight loss drugs do not usually exclude cardiovascular treatment.
Who this fits: adults with an established cardiovascular diagnosis, such as a previous heart attack or stroke, or known narrowing of the arteries. It is not for people who simply have risk factors and no diagnosis.
Route two: sleep apnea, using Zepbound
In December 2024, the FDA approved Zepbound (tirzepatide) for moderate to severe obstructive sleep apnea in adults with obesity. It was the first medication ever approved for sleep apnea, which had previously been treated with CPAP machines and surgery.
Sleep apnea is worth raising because it is common, it is badly underdiagnosed, and it is easy to test for. Many people who have been trying to get a GLP-1 covered for weight already have symptoms: loud snoring, waking up gasping, morning headaches, heavy daytime sleepiness. A sleep study can confirm it.
If you have moderate to severe obstructive sleep apnea and obesity, this is a documented, approved use with real trial evidence behind it, and it sits outside the weight management exclusion.
Route three: type 2 diabetes
This is the widest door of the three by a long way. Ozempic and Mounjaro are approved for type 2 diabetes, and almost every state Medicaid program covers at least one GLP-1 for it. Most commercial plans do too.
The catch is that you need the diagnosis. Prediabetes usually does not qualify, and plans check. Prior approval is still normally required, and many plans want to see that you have tried metformin first.
One thing to be clear about: Ozempic and Mounjaro are approved for diabetes, not for weight loss. Wegovy and Zepbound are the versions approved for weight management. Asking for a diabetes drug purely to lose weight is one of the most common reasons a request gets turned down.
What this does not mean
It is worth being blunt here, because this is the part that gets misread.
You cannot choose an indication because it is easier to get approved. If you do not have heart disease, Wegovy's heart indication is not available to you. If you do not have sleep apnea, Zepbound's sleep apnea indication is not either. Your clinician has to be able to document the condition honestly, and plans do ask for the evidence: a diagnosis code, a sleep study, a cardiology record.
What you can reasonably do is ask whether anything already in your medical history fits. A lot of people have an undiagnosed or unmentioned condition sitting in their notes that nobody connected to this question.
How to raise it with your clinician
Bring the denial letter with you. The reason code on it tells your clinician what was actually refused, which is usually more specific than "denied."
Then ask three questions. Do I have any cardiovascular diagnosis on file? Have I ever been assessed for sleep apnea, and should I be? Does my blood sugar history meet the threshold for type 2 diabetes rather than prediabetes?
If the answer to any of them is yes, the next prior authorization request can be built on that condition instead. If the answer is no to all three, the honest position is that the weight management route is your route, and the thing to do is appeal it properly. We have a separate guide on what to do when your GLP-1 is denied.
While you sort it out
Appeals and new prior authorization requests take time, often several weeks. If you need to bridge the gap, manufacturer savings programs and cash pay clinics are the usual options. Our GLP-1 pricing guide covers what these actually cost, and you can find a clinic near you to compare.
Sources: FDA approval announcements from Novo Nordisk (Wegovy, March 8, 2024) and Eli Lilly (Zepbound, December 2024); Social Security Act section 1927(d)(2); KFF Medicaid GLP-1 coverage data, January 2026. This is general information, not medical or insurance advice. Talk to your clinician about your own situation.
Frequently asked questions
Can my doctor just write a different diagnosis to get it approved?
No. That is insurance fraud, and it puts your clinician's licence at risk as well as your coverage. The point of these other routes is that some people genuinely have a qualifying condition and were never asked about it.
Does Medicare cover GLP-1s for these other conditions?
Yes, and Medicare changed on this recently. Part D was barred for years from paying for a drug prescribed purely for weight loss, which made the heart and sleep apnea routes the only way in. Since July 1, 2026 the Medicare GLP-1 Bridge has covered Wegovy and Zepbound for weight loss at a flat $50 a month for eligible Part D enrollees, running through December 31, 2027. The other indications still matter if you are not eligible for the Bridge. See our Medicare GLP-1 coverage page.
My state Medicaid does not cover weight loss drugs. Do these routes still apply?
Yes, and this is where they matter most. A state that uses the section 1927(d)(2) exclusion is excluding the weight loss use, not the medicine. Coverage for diabetes is nearly universal, and the newer heart and sleep apnea indications sit outside the weight loss exclusion too. Check your state's Medicaid position.
Which is easier to get approved, the heart route or the sleep apnea route?
Neither is reliably easier, because it depends entirely on what you can document. The heart indication needs an existing cardiovascular diagnosis. The sleep apnea indication needs a sleep study showing moderate to severe obstructive sleep apnea. Whichever you can actually evidence is the one to use.